Novo Nordisk A/S (NVO) Analysts See $0.61 EPS

October 14, 2018 - By Dolores Ford

Novo Nordisk A/S (NYSE:NVO) Logo

Analysts expect Novo Nordisk A/S (NYSE:NVO) to report $0.61 EPS on November, 7.They anticipate $0.01 EPS change or 1.61 % from last quarter’s $0.62 EPS. NVO’s profit would be $1.49 billion giving it 17.43 P/E if the $0.61 EPS is correct. After having $0.68 EPS previously, Novo Nordisk A/S’s analysts see -10.29 % EPS growth. The stock increased 2.38% or $0.99 during the last trading session, reaching $42.53. About 1.89M shares traded or 23.44% up from the average. Novo Nordisk A/S (NYSE:NVO) has risen 0.93% since October 14, 2017 and is uptrending. It has underperformed by 14.69% the S&P500.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. The company has market cap of $103.66 billion. It operates in two divisions, Diabetes and Obesity Care, and Biopharmaceuticals. It has a 17.04 P/E ratio. The Diabetes and Obesity Care segment provides insulins, GLP-1 analog, and oral anti-diabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles.

More notable recent Novo Nordisk A/S (NYSE:NVO) news were published by: which released: “Novo Nordisk lays off 400 staff in R&D unit” on September 18, 2018, also with their article: “Premarket analyst action – healthcare” published on October 09, 2018, published: “Lilly’s dual GIP and GLP-1 receptor agonist shows positive action in mid-stage T2D study; shares up 3% premarket” on October 04, 2018. More interesting news about Novo Nordisk A/S (NYSE:NVO) were released by: and their article: “Novo Nordisk: Time To Sell?” published on October 09, 2018 as well as‘s news article titled: “Novo’s once-weekly somapacitan on par with daily Norditropin in mid-stage study” with publication date: September 28, 2018.

Novo Nordisk A/S (NYSE:NVO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News